DCVax-L, Northwest Biotherapeutics

Drug: DCVax-L
Company: Northwest Biotherapeutics
Phase: Phase III
Class: Cancer vaccine
2020 sales: $2.04 billion
Net present value: $5.5 billion

DCVax-L is a cancer vaccine, which in and of itself is grounds for controversy. Some analysts don't give this one a chance because it is a cancer vaccine based on dendritic cell technology--a field that has seen weak responses in a slate of studies. And others hate it because the company has taken the, um, unconventional approach of regularly touting individual patients' positive responses as evidence of broad efficacy. It's fine to use anecdotes to illustrate a broadly positive efficacy profile--provided you have the data in hand to back it up. Northwest Bio ($NWBO) has also trumpeted a decision in Germany to make it available to brain cancer patients. Despite the controversy, EvaluatePharma sees this one as a potential standout, a new entry that is likely to get plenty of careful attention.

For more:
Northwest Bio begins German vax trial as glioblastoma market poised to double
ASCO preview: What's the outlook for cancer vaccines?
Northwest Bio, NewLink proceed with cancer vax trials to mixed reviews

DCVax-L, Northwest Biotherapeutics
Read more on

Suggested Articles

Cour unveiled phase 2 data showing that its treatment cut levels of pro-inflammatory cytokines and protected the gut in patients with celiac disease.

Three years after Bayer and gene-editing biotech CRISPR Therapeutics joined forces to launch and run Casebia Therapeutics.

Fresh off Tilos Therapeutics’ $773 million sale to Merck, Barbara Fox is taking the helm of another Cambridge-based company: Rheos Medicines.